Government Licenses Viral Peptide to Fight Liver Cancer
Published Date: 7/2/2026
Notice
Summary
The National Cancer Institute has created a special viral peptide that could help prevent and treat a serious liver cancer called HCC. This new discovery might lead to a vaccine or therapy that boosts the immune system to fight cancer better. Researchers and companies interested in developing this treatment can now license the technology, opening doors for faster progress and potential health benefits worldwide.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Potential New HCC Vaccine/Therapy
Researchers at the NCI report that a synthetic CE1 peptide can elicit T cell responses against HCC cells and could be developed as an immunotherapy or CE1-based HCC vaccine. The notice says such novel treatments could offer substantial public health benefits for people at risk of or living with hepatocellular carcinoma worldwide.
NIH Offers CE1 Peptide License
The National Cancer Institute (NCI) is offering a license and co-development opportunities for a viral peptide (CE1) intended for hepatocellular carcinoma (HCC) prevention and treatment (NIH Reference Number E-023-2024). The technology is at the Discovery stage and is being offered for commercial development; a related patent application (PCT/US2025/059785) was filed December 16, 2025.
New Diagnostic and Monitoring Uses
The NCI lists potential commercial applications including a predictive biomarker for HCC risk, a serological response test, patient stratification for CE1-based therapy, and tools to monitor vaccine efficacy. These applications could be developed and licensed for clinical use alongside CE1-based therapeutics.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-22871, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early December 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for eye disease, neuronal injury, infectious diseases, and related projects. No public access is allowed to protect private info and trade secrets, but these reviews help decide who gets research money.
2026-22550, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding two closed virtual meetings on November 30, 2026, to review important grant applications. These meetings affect researchers applying for funding in cardiovascular sciences and tobacco regulatory science. No public access is allowed to protect private info and trade secrets, and the reviews help decide who gets research money.
2026-22558, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early December 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for health-related projects, ensuring privacy for sensitive information. No direct money changes are announced, but these reviews help decide who gets research grants.
2026-22339, Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human
The National Institutes of Health plans to give AntaraCore Systems, Inc. an exclusive license to use new catheter technology that treats dangerous heart rhythm problems called ventricular arrhythmia. This means AntaraCore will have special rights to develop and sell this life-saving treatment. If you want to comment or apply for a license, you must do so by December 2, 2026.
2026-22196, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a public meeting on May 12, 2027, to discuss important council business and review grant applications. People interested can attend in person or online, but space is limited and some parts of the meeting will be private to protect sensitive information. This meeting affects researchers and organizations seeking funding and sets the stage for future diabetes and kidney disease research support.
2026-22111, Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is holding a virtual meeting on June 4, 2027, to share updates and review grant applications and staff performance. The first half is open to the public, while the second half is private to protect personal privacy. This meeting affects researchers and staff involved with NICHD grants and projects, with no direct cost changes announced.
Previous / Next Documents
Previous: 2026-13479, Government Owned Invention Available for License: Chimeric VLP Vaccines To Prevent HTLV-1 Infection
The National Cancer Institute has created a new vaccine to stop HTLV-1, a virus that can cause serious diseases like leukemia. Right now, no vaccine exists, so this invention could protect millions, especially in underserved areas. They’re looking for partners to help develop and license this promising vaccine, which could save lives and reduce healthcare costs in the near future.
Next: 2026-13486, Implementing Voluntary Agreements Under the Defense Production Act
The Department of Energy is rolling out a new voluntary agreement to boost the U.S. nuclear fuel supply chain, helping keep energy secure and strong. This affects companies in the nuclear fuel cycle, encouraging teamwork without forcing anyone. The plan kicks in after October 2025 and aims to support national security while keeping energy flowing smoothly.